| Literature DB >> 35052900 |
Andrea Feuerstein1, Nelly Scuda1, Corinna Klose1, Angelika Hoffmann1, Alexander Melchner2, Kerstin Boll1, Anna Rettinger1, Shari Fell3, Reinhard K Straubinger4, Julia M Riehm2.
Abstract
Worldwide, enterotoxigenic Escherichia coli (ETEC) cause neonatal diarrhea and high mortality rates in newborn calves, leading to great economic losses. In Bavaria, Germany, no recent facts are available regarding the prevalence of virulence factors or antimicrobial resistance of ETEC in calves. Antimicrobial susceptibility of 8713 E. coli isolates obtained from 7358 samples of diseased or deceased diarrheic calves were investigated between 2015 to 2019. Considerably high rates of 84.2% multidrug-resistant and 15.8% extensively drug-resistant isolates were detected. The resistance situation of the first, second and third line antimicrobials for the treatment, here amoxicillin-clavulanate, enrofloxacin and trimethoprim-sulfamethoxazole, is currently acceptable with mean non-susceptibility rates of 28.1%, 37.9% and 50.0% over the investigated 5-year period. Furthermore, the ETEC serotypes O101:K28, O9:K35, O101:K30, O101:K32, O78:K80, O139:K82, O8:K87, O141:K85 and O147:K89, as well as the virulence factors F17, F41, F5, ST-I and stx1 were identified in a subset of samples collected in 2019 and 2020. The substantially high rates of multi- and extensively drug-resistant isolates underline the necessity of continuous monitoring regarding antimicrobial resistance to provide reliable prognoses and adjust recommendations for the treatment of bacterial infections in animals.Entities:
Keywords: E. coli; antimicrobial resistance; calves; enteritis; extensively drug-resistant; multidrug-resistant; serotypes; virulence
Year: 2021 PMID: 35052900 PMCID: PMC8772957 DOI: 10.3390/antibiotics11010023
Source DB: PubMed Journal: Antibiotics (Basel) ISSN: 2079-6382
Figure 1Minimum inhibitory concentration (MIC) distribution of 8713 E. coli isolates on 12 antimicrobial agents from 11 antimicrobial classes. The three first lines represent the clinically relevant substances, first to third treatment choices in buiatrics. The red line demarcates the breakpoint towards resistance, the green line a breakpoint towards intermediate. Regarding the two combination compounds, only the concentration of the former substance is presented; the ratio of amoxicillin:clavulanic acid is 2:1 (1), concentration ratio of trimethoprim:sulfamethoxazole is 1:19 (2). Tulathromycin has not been tested in the first quarter of 2015 (3). The summation of intermediate and resistant isolates was named non-susceptible (4). Some results were not evaluable (5).
Figure 2The mean value (bold) and the five-year trend on non-susceptible E. coli isolated from calves revealed the highest proportion of isolates against trimethoprim-sulfamethoxazole, followed by enrofloxacin and amoxicillin-clavulanate. The trends regarding enrofloxacin and amoxicillin-clavulanate remain at a stable level and rather tend towards a decrease regarding the number of non-susceptible isolates. The graph of non-susceptible isolates regarding trimethoprim-sulfamethoxazole reveals a decrease, 2016–2017, followed by a steep increase of non-susceptible isolates in 2019. The corresponding statistic parameters are presented in Table 1.
Statistic parameters regarding the increase or decrease of resistance values within the five-year period for the three clinically relevant antimicrobials (Figure 2).
| Antimicrobial | Years | OR | CI (95%) |
|---|---|---|---|
| amoxicillin-clavulanate | 2015–2019 | 0.95 | 0.92–0.98 1 |
| enrofloxacin | 2015–2019 | 0.91 | 0.88–0.94 1 |
| 2015–2017 | 0.92 | 0.85–1.0 1 | |
| trimethoprim-sulfamethoxazole | 2015–2019 | 1.0 | 0.97–1.03 |
| 2017–2019 | 1.11 | 1.03–1.19 1 |
OR: odds ratio, CI: confidence interval, 1 p-value (Wald test) < 0.05.
Figure 3The classification of 8713 E. coli into extensively drug-resistant and multi drug-resistant isolates was carried out according to the expert proposal for standard definitions for acquired resistance. We categorized eight potential pandrug-resistant isolates in the category extensively drug resistant, as we only tested antimicrobials licensed for the veterinary use and did not include the latest antimicrobials available on the market.
The serologic and molecular characterization revealed 13 different serotypes known to be pathogenic for cattle and other species. Furthermore, four different genotypes were detected with five different coding sequences for fimbria and/or toxins in one or more isolates. Some of the isolates were untypeable/ seronegative and did not reveal any of the investigated virulence factors (green box).
| Serotype | Additionally Known for | Number of | Non-Virulent | Molecular Results | |||
|---|---|---|---|---|---|---|---|
| F17 | F5ST-I | F5F41ST-I | stx1 | ||||
| O9:K35 | 6 | 5 | 1 | ||||
| O9:K35/F5 | 1 | 1 | |||||
| O101:K28 | 6 | 6 | |||||
| O101:K28/F5 | 3 | 3 | |||||
| O101:K30 | 1 | 1 | |||||
| O101:K30/F5 | 3 | 3 | |||||
| O101:K32 | 3 | 3 | |||||
| O78:K80 | Human/sheep | 3 | 3 | ||||
| O8:K87 | Swine | 3 | 3 | ||||
| O139:K82 | Swine | 2 | 2 | ||||
| O139:K82/F4 | Swine | 5 | 4 | 1 | |||
| O141:K85 | Swine | 1 | 1 | ||||
| O147:K89 | Swine | 1 | 1 | ||||
| untypeable | 29 | 20 | 7 | 2 | |||
| seronegative | 41 | 37 | 4 | ||||
| Total | 108 | 84 | 15 | 3 | 4 | 2 | |
In all, 16 different polyvalent and monovalent (mono) antisera were used for the agglutination and the characterization of E. coli. The listed serotypes are known for their pathogenicity in humans and farm animals.
| Antiserum for | Respective Follow Up | Specific Serotypes Occur in Cattle, but Are Found as Well/Especially in |
|---|---|---|
| Polyvalent anti- | ||
| O9:K35, mono | ||
| O101:K28, mono | ||
| O101:K30, mono | ||
| O101:K32, mono | ||
| F5, mono | ||
| O78:K80, mono | Human, sheep | |
| Polyvalent anti- | Swine | |
| O8:K87, mono | ||
| O138:K81, mono | ||
| O139:K82, mono | ||
| O141:K85, mono | ||
| O147:K89, mono | ||
| O149:K91, mono | ||
| F4, mono | ||
| O157:H7, mono | Association with |
Targets and primers for the molecular characterization of E. coli isolated from calves.
| Target Protein | Gene(s) | Primer | Oligo Sequence (5’ -> 3’) | Size (bp) | Melting Temperature (°C) ± 0.2 °C | Reference | Reference Isolate |
|---|---|---|---|---|---|---|---|
| F4 | F4_F | GGTGGAACCAAACTGACCATTAC | 102 | 81.0 | [ | 7156 | |
| Fimbria/outer membrane protein | F4_R | TCCATCTACACCACCAGTTACTGG | |||||
| F5 | F5_F | TTGGAAGCACCTTGCTTTAACC | 101 | 77.4 | [ | 7159 | |
| F5_R | TCACTTGAGGGTATATGCGATCTTT | ||||||
| F6 | F6_F | GCGGATTAGCTCTTTCAGACCA | 102 | 83.2 | [ | 7155 | |
| F6_R | TGACAGTACCGGCCGTAACTC | ||||||
| F17 | F17_F | ACTGAGGATTCTATGCRGAAAATTCAA | 83 | 79.7 | [ | 5397 | |
| F17_R | CCGTCATAAGCAAGCGTAGCAG | ||||||
| F18 | F18_F | CCTGCTAAGCAAGAGAATATATCCAGA | 82 | 73.3 | [ | 7160 | |
| F18_R | AGAACATATACTCAGTGCCAACAGAGAT | ||||||
| F41 | F41_F | CCTTTGTCATTTGGTGCGG | 101 | 81.5 | [ | 7159 | |
| F41_R | TCAAATACTGTACCAGCAGAACCAC | ||||||
| O157 (rfbE) | O157_F | CGATGAGTTTATCTGCAAGGTGAT | 88 | 78.3 | [ | DSMZ 19206 | |
| O157_R | TTTCACACTTATTGGATGGTCTCAA | ||||||
| Adhesin | intimin (eaeA) | Intimin_F | CCAGCTTCAGTCGCGATCTC | 91 | 86.1 | [ | 7158 |
| Intimin_R | GGCCTGCAACTGTGACGAA | ||||||
| Hemolysin | enterohemolysin (ehxA) | ehec-F2 | CGTTAAGGAACAGGAGGTGTCAGTA | 142 | 79.5 | [ | DSMZ 19206 |
| ehec-R | ATCATGTTTTCCGCCAATGAG | ||||||
| Toxin | heat-labile toxin (LT) | LT_F | CTGCCATCGATTCCGTATATGAT | 81 | 75.3 | [ | 7157 |
| LT_R | CAGAACTATGTTCGGAATATCGCA | ||||||
| heat-stabile toxin (ST-I) | ST-I_F | TACCTCCCGTCATGTTGTTTCAC | 101 | 76.1 | [ | 7155 | |
| ST-I_R | CCTCGACATATAACATGATGCAACTC | ||||||
| heat-stabile toxin (ST-II) | St-II_F | TTTTTCTATTGCTACAAATGCCTATGC | 101 | 75.9 | [ | 7156 | |
| St-II_R | AACCTTTTTTACAACTTTCCTTGGC | ||||||
| Shiga toxin 1 (stx1) | Stx1_F | TCCCCAGTTCAATGTAAGATCAAC | 81 | 79.0 | [ | 7158 | |
| Stx1_R | TTTCGTACAACACTGGATGATCTCA | ||||||
| Shiga toxin 2 (stx2) | Stx2_F | GAGTGACGACTGATTTGCATTCC | 82 | 84.6 | [ | 7158 | |
| Stx2_R | CCATGACAACGGACAGCAGTT |